Zobrazeno 1 - 10
of 42
pro vyhledávání: ''
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Autor:
Hiroaki Toba, Hirokazu Takechi, Mariko Aoyama, Takahiro Yoshida, Masami Morimoto, Akira Tangoku, Misako Nakagawa
Publikováno v:
Clinical breast cancer. 20(6)
Purpose To evaluate the efficacy, toxicity, maximum tolerated dose, and recommended dose of triweekly nab-paclitaxel (nab-PTX) and S-1 combination chemotherapy for patients with metastatic breast cancer. Patients and Methods This phase 1 study was co
Autor:
Vijayakrishna K. Gadi, Carol Van Haelst, Eve T. Rodler, Quan Vicky Wu, Mary W. Redman, Isaac C. Jenkins, Jeanne Anderson, Kelsey Baker, Julie R. Gralow, Mitchell Garrison, Larissa A. Korde, Julie C. Smith, Brenda F. Kurland, Jennifer M. Specht, Lynn Symonds, Hannah M. Linden
Publikováno v:
Clinical breast cancer. 19(2)
Introduction Angiogenesis and epidermal growth factor receptor signaling are potential therapeutic targets in triple negative breast cancer (TNBC). We hypothesized that targeting these critical pathways would prolong progression-free survival with fi
Autor:
Donald W. Northfelt, Winston Tan, Edith A. Perez, Matthew P. Goetz, James N. Ingle, Alvaro Moreno-Aspitia, Jacob B. Allred
Publikováno v:
Clinical Breast Cancer. 16:82-86
Introduction Histone deacetylase inhibitors have been found to restore sensitivity to the estrogen receptor in endocrine-resistant and triple-negative breast cancer cell lines. We decided to test panobinostat, a pan-histone deacetylase inhibitor, bec
Autor:
Charalampos Christofillakis, Konstantinos Kalbakis, Nikolaos F Pistamaltzian, Charalampos Kourousis, Dimitris Mavroudis, Aris Polyzos, Nikolaos Kentepozidis, Emmanouil Saloustros, Michail Nikolaou, L. Vamvakas, Vasilios Georgoulias
Publikováno v:
Clinical breast cancer. 18(1)
Background Triple-negative breast cancer (TNBC) lacks a standard targeted therapeutic strategy and is treated with conventional cytotoxic agents. Because of the sensitivity of TNBC to platinum compounds and the synergistic effect of bevacizumab with
Autor:
Benedetta Montagna, M.R. Strada, Antonio Bernardo, Guido Poggi, M. Frascaroli, Alessio Amatu, Cristina Teragni, Giovanni Bernardo, Federico Sottotetti, Raffaella Palumbo, Alberto Riccardi, Barbara Tagliaferri
Publikováno v:
Clinical Breast Cancer. 12:30-39
Background The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2–negative (HER – ) metastatic breast cancer (MBC). Patients and Methods Patie
Autor:
Philipp Hemmati, Silvia Lehenbauer-Dehm, Bernd Flath, Peter Schmid, Christian Jehn, Sherko Kümmel
Publikováno v:
Clinical breast cancer. 16(6)
Background Pegylated liposomal doxorubicin (PLD) has shown to be as effective as conventional doxorubicin in the treatment of metastatic breast cancer but provides a lower risk of cardiotoxicity. This phase 2 study in heavily pretreated patients with
Autor:
Denise A. Yardley, Brooke R. Daniel, Yuval Naot, Elizabeth R. Vazquez, Howard A. Burris, Roger Inhorn, John D. Zubkus, John D. Hainsworth, Cassie M. Lane
Publikováno v:
Clinical Breast Cancer. 10:367-372
Background Neoadjuvant anthracycline/taxane combinations, with or without gemcitabine, produce pathologic complete responses (pCRs) in 15%-25% of patients. In this multicenter phase II study, we attempted to increase efficacy and decrease toxicity of
Autor:
F. Anthony Greco, Sarah Hanson, J. H. Barton, David R. Spigel, Howard A. Burris, John D. Hainsworth, Denise A. Yardley
Publikováno v:
Clinical Breast Cancer. 9:178-183
Background The use of trastuzumab in combination with either a taxane or vinorelbine has improved the efficacy of treatment for women with HER2-positive (HER+) breast cancer. We investigated the activity and toxicity of the gemcitabine/trastuzumab co
Autor:
Lorinda Simms, Allen S. Melemed, Jane E. Latz, Hans Wildiers, Robert Paridaens, Celia Tosello Oliveira, Luc Dirix, Herlinde Dumez, Ana Alvarez, A Prové
Publikováno v:
Clinical Breast Cancer. 7:861-866
Background Pemetrexed and epirubicin are each active in patients with advanced/metastatic breast cancer (MBC). This phase I/II study evaluated these drugs as a combination regimen. Patients and Methods Women with locally advanced or MBC were enrolled